| Hao Liu,Yujing Zhang,Jingyi Li,Rong Yan. Analysis of the adverse reactions of atezolizumab: A real-world study based on FAERS database. Oncol Transl Med, 2021, 7: 88-94. |
| Analysis of the adverse reactions of atezolizumab: A real-world study based on FAERS database |
| Received:July 13, 2020 Revised:April 08, 2021 |
| View Full Text View/Add Comment Download reader |
| KeyWord:atezolizumab; adverse reactions; Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database; rational drug use |
| Author Name | Affiliation | Department | | Hao Liu | The First Affiliated Hospital of Xi''an Jiaotong University, Xi''an , China | Department of Surgical Oncology | | Yujing Zhang | The First Affiliated Hospital of Xi''an Jiaotong University, Xi''an , China | Department of Surgical Oncology | | Jingyi Li | Xi''an Jiaotong University, Xi''an , China | College of Stomatology | | Rong Yan | The First Affiliated Hospital of Xi''an Jiaotong University, Xi''an , China | Department of Surgical Oncology |
|
| Hits: 3494 |
| Download times: 3639 |
| Abstract: |
| Objective In this study, we aimed to determine the incidence of adverse drug reactions (ADRs) of
atezolizumab, identify ADR signals that are significantly related to atezolizumab, and provide a reference
for the rational use of atezolizumab in the clinic through the statistical analysis of its adverse drug events
(ADEs) reported in the American Food and Drug Administration (FDA) Adverse Event Reporting System
(FAERS) database.
Methods In total, 4796 cases of atezolizumab ADEs reported in the American FAERS database from
2017 to 2019 were retrospectively analyzed.
Results The top three ADEs were febrile neutropenia (3.7%), anemia (2.9%), and acute renal failure
(2.3%). In addition, the incidence rates of some ADEs were significantly different according to sex and age.
The systematic organ classification of atezolizumab ADEs involved 32 systems, among which the top three
were blood and lymphatic system disorders (585 cases, 12.2%), gastrointestinal disorders (433 cases,
9.0%), and infections and infestations (401 cases, 8.4%). The reporting odds ratio (ROR) method was
used to detect the ADR signals of atezolizumab. The ROR (95% confidence interval) of the top ADE, febrile
neutropenia, was 39.236 (33.757–45.604). In addition, we found 121 cases of complications associated
with immune-related ADEs.
Conclusion The ADRs of atezolizumab reported in the FAERS database were consistent with those
mentioned in the instructions for atezolizumab use, suggesting that atezolizumab has an acceptable and
controllable drug effect. |
| Close |
|
|
|